First published 9/28/2026, 9:35:15 AM · Last updated 9/28/2026, 9:35:15 AM

Prognostic impact of immune-related adverse events in non-completers of durvalumab consolidation therapy for non-small cell lung cancer: a single-center retrospective cohort study

Published 2026-09-01, this single-center retrospective cohort journal article analyzes prognosis in patients who did not complete durvalumab consolidation therapy for non-small cell lung cancer. The study specifically examines associations with immune-related adverse events.

Categories: public-health, science-and-space

Generated scores

Scores are based on the cited reporting and use a 1–10 scale. Read the methodology.

Confidence: 5/10How certain the assessment is based on the clarity and evidence in the cited reporting.
Geographic reach: 1/10How widely the event reaches, from a local area (1) to worldwide impact (10).
Global importance: 2/10The event's broader significance, from limited importance (1) to major global importance (10).
Impact magnitude: 3/10The scale or severity of the real-world impact, from minor (1) to extreme (10).
Positivity: 2/10How harmful or beneficial the event is, from strongly harmful (1) to strongly positive (10).
Urgency: 2/10How time-sensitive the event is, from low urgency (1) to immediate attention needed (10).

Why it matters

The study evaluates prognostic associations between treatment-related immune adverse events and outcomes in a defined patient subgroup.

Sources

Prognostic impact of immune-related adverse events in non-completers of durvalumab consolidation therapy for non-small cell lung cancer: a single-center retrospective cohort study

Report an issue